Mursla Bio has joined the ABHI US Accelerator program to support the US launch of EvoLiver, an FDA-designated liver cancer surveillance test, gaining access to 300-plus healthcare leaders across 35 hospitals and 20 health systems.
Research demonstrates an automated next-generation sequencing workflow designed to reduce hands-on time while delivering next-day CGP results.
The FDA has granted Breakthrough Device Designation to Breath Diagnostics Inc.'s OneBreath, a breath-based test that assesses postoperative pneumonia risk in cardiac surgery patients using a single preoperative sample.
The Association for Diagnostics & Laboratory Medicine is urging Congress and federal agencies to update regulations to address AI bias in clinical lab systems, citing risks to marginalized patient groups from models trained on limited data.
Research in bone marrow transplant patients with blood cancers and febrile neutropenia suggests the host-response test may help identify infection in high-risk populations.
